Pfizer, Inc. vs Arcus Biosciences, Inc. — Stock Comparison
Q·Score Breakdown
6.5
Neutral
Overall
5.7
Neutral
Quality
Health
Growth
Valuation
Sentiment
PFE
Strong profitability with 12% net profit margins.
⚠ analyst sentiment is cautious.
RCUS
Clean balance sheet with low leverage (0.3× debt-to-equity).
⚠ currently unprofitable (-143% margin).
Analyst Consensus
HOLD
Target $29.00 (+10.2%)
27 analysts
BUY
Target $34.00 (+32.4%)
10 analysts
Fundamentals
PFE
RCUS
19.4×
Trailing P/E
—
9.4×
Forward P/E
-7.3×
12.4%
Profit Margin
-142.9%
75.8%
Gross Margin
-111.7%
8.9%
ROE
-63.3%
-1.2%
Revenue Growth
26.9%
—
Earnings Growth
—
0.39
Beta
0.86
—
Price / Book
—
$149.8B
Market Cap
$3.2B
$22 – $29
52-Week Range
$7 – $29
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →